pharmaceuticals

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have lost more than 10 percent over the past year, but one analyst is confident enough to call for upside to the stock. The Analyst Credit Suisse's Martin Auster initiated coverage of Alexion Pharmaceuticals' stock with an Outperform...

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.  The Analyst Goldman Sachs' Jami Rubin...

After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...

The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse. The Analyst Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...

Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s business has faced multiple pressures, including industry-wide price erosion, a legal battle for possible collusion in generic drug pricing along with a management transition. At the same time, some analysts see the bullish case for owning the...

Veeva Systems Inc (NYSE: VEEV) reported third-quarter results Tuesday that included a top- and bottom-line beat and encouraging guidance for the coming fiscal quarter and next year. The Analyst KeyBanc Capital Markets' Brent Bracelin maintains an Overweight rating on Veeva Systems' stock...

Allergan plc Ordinary Shares (NYSE: AGN) have seen heavy selling pressure throughout parts of 2017, but some analysts are encouraging investors to take advantage of the weakness. The Analyst Morgan Stanley's David Risinger upgraded Allergan's stock rating from Equal-weight to Overweight...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) traded up as much as 82.6 percent Thursday after reporting positive top-line results for its uncontrolled phase 2 study of ZYN002 in children with Fragile X syndrome. The synthetic cannabinoid transdermal gel “successfully met its primary endpoint...

It was a good month for Insmed Incorporated (NASDAQ: INSM). On Sept. 5, the company released positive phase 3 data for ALIS in the treatment of nontuberculous mycobacterial lung disease, inspiring a doubling in stock price and “elation” in the long-toiling staff. “This data...

Pharmaceuticals need a palliative in the age of Donald Trump. Even before taking office, the president threatened the industry’s profit model with a commitment to lower treatment prices. He accused drugmakers of “getting away with murder” and suggested “new bidding...

It’s taking time, but three days after Gilead Sciences, Inc. (NASDAQ: GILD) announced its acquisition of Kite Pharma Inc (NASDAQ: KITE), the Street seems to be deciding it’s a good thing. Gilead’s stock traded up a modest 2.5 percent and three analysts reiterated Hold ratings...

It turns out you can have too much of a good thing. The 1,000-plus immunotherapy trials and competition to develop proprietary versions of virtually the same drugs may prove inhibitory to cancer research, according to the New York Times. The conditions leave clinical researchers competing for the...

Analysts at Cantor Fitzgerald turned incrementally bullish on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the once-troubled pharmaceutical company is showing signs of sustaining momentum. Cantor Fitzgerald's Louise Chen maintains an Overweight rating on Valeant's stock with a price...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) rose about 14 percent early Tuesday morning after the troubled pharmaceutical company reported an encouraging first quarter earnings report and guidance raise. Valeant reported a first quarter GAAP earnings per share of $1.79, which marks an...